Sandra Milev
Research Subjects
Research Interests
Sandra Milev has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Sardesai
Evidera Inc., San Francisco, USA
1 shared publication Alexia Kieffer
Sanofi , Lyon , France
1 shared publicationDenise Zou
Evidence Synthesis, Modeling and Communication, Evidera, San Francisco, California
1 shared publicationHannah K. Gaggin
Department of Medicine and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication- James L. Januzzi
Baim Institute for Clinical Research, Massachusetts General Hospital, Boston, USA
1 shared publication - Jason K. H. Lee
Sanofi Pasteur, Toronto, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 15 August 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (Supplement) , S282-S292
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods: A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab’s impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results: Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions: An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.
- 15 August 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (Supplement) , S282-S292
Open AccessExpected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods: A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab’s impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results: Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions: An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.
- 19 January 2022
- Published by Elsevier in Value in Health
- Vol. 25 (1) , S83
POSB115 Approaches for Modeling Treatment Effect Waning in Markov Cohort Models in Nice Reviews of Non-Oncology Agents
- 19 January 2022
- Published by Elsevier in Value in Health
- Vol. 25 (1) , S83
POSB115 Approaches for Modeling Treatment Effect Waning in Markov Cohort Models in Nice Reviews of Non-Oncology Agents
- Open Access
- 1 May 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 147, 61-69
Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department
- 1 May 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 147, 61-69
Open AccessEconomic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department